Athenex is a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer.

Our proprietary delivery system allows a class of existing high potency oncology drugs to be dosed orally to improve patient outcomes and quality of life.

Our Src Kinase Inhibitors also bind to a novel site on tubulin heterodimers thereby broadening their anti-tumor activity beyond that provided by Src inhibition alone.

Transformative, oncology-focused and highly synergistic pipeline with late stage product candidates.

Important Information

Click Here for Important information for Health Care Providers regarding Sodium Bicarbonate Injection
Click Here for Athenex Anti-Capital Punishment Statement

Athenex IPO on the NASDAQ Stock Market, June 14, 2017

On June 14, 2017, Athenex celebrated its initial public offering (IPO) at the Nasdaq MarketSite in Times Square.

Photography by Christopher Galluzzo / Nasdaq, Inc.
Photography by Christopher Galluzzo / Nasdaq, Inc.
Governor Cuomo Announces Major Expansion of Athenex — Creating 1,400 Jobs in Western New York

Rendering of new 300,000 square foot facility

Athenex (formerly Kinex) to invest $1.62 billion in drug discovery and advanced manufacturing partnership, creating 900 jobs in Dunkirk and 500 jobs in Buffalo over the next ten years.

State investing $225 million to support the Buffalo Medical Innovation and Commercialization Hub and help create new opportunities for the region.

Governor Andrew M. Cuomo recently announced a major expansion of Athenex that will create 1,400 jobs throughout Western New York. This announcement, made possible by a partnership with the SUNY Polytechnic Institute, includes a major expansion of Athenex’s North American headquarters at the Conventus Building in Buffalo, as well as the creation of a state-of-the-art, 300,000 square foot manufacturing facility in Dunkirk.

Read more

Athenex Completes Public/Private Partnership Agreement with Chongqing, China To Construct Two New Pharmaceutical Manufacturing Plants

Athenex recently announced the completion and execution of a definitive agreement with the Banan District in Chongqing, China to construct two separate pharmaceutical manufacturing plants on Banan sites already identified and selected by Athenex management. Under the terms of the agreement, Banan will provide the funding for the land and construction of the manufacturing plants according to Athenex specifications, and Athenex will equip the facilities.

Read more

Athenex Announces Phase II Clinical Study Results for KX2-391 Ointment for the Treatment of Actinic Keratosis in the American Academy of Dermatology Meeting

BUFFALO, N.Y., Feb. 20, 2018 (GLOBE NEWSWIRE) — Athenex (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Phase II clinical study data for KX2-391 for the treatment of actinic keratosis was presented by Dr. Seth Forman of Forward Clinical Trials, Tampa, at the American Academy of Dermatology Annual Meeting on February 17, 2018 in San Die…  Read more

Athenex to Present at 2018 RBC Capital Markets Healthcare Conference

BUFFALO, N.Y., Feb. 16, 2018 (GLOBE NEWSWIRE) — Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced Dr. Johnson Lau, Chief Executive Officer, will present at the 2018 RBC Capital Markets Healthcare Conference in New York City on Wednesday, February 21, 2017 at 11:00 am EST. The presentation will be webcasted, and can be accessed at…  Read more